674 related articles for article (PubMed ID: 24821328)
1. Beyond intestinal soap--bile acids in metabolic control.
Kuipers F; Bloks VW; Groen AK
Nat Rev Endocrinol; 2014 Aug; 10(8):488-98. PubMed ID: 24821328
[TBL] [Abstract][Full Text] [Related]
2. Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion.
Sonne DP; Hansen M; Knop FK
Eur J Endocrinol; 2014 Aug; 171(2):R47-65. PubMed ID: 24760535
[TBL] [Abstract][Full Text] [Related]
3. Bile acid sequestrants and the treatment of type 2 diabetes mellitus.
Staels B; Kuipers F
Drugs; 2007; 67(10):1383-92. PubMed ID: 17600387
[TBL] [Abstract][Full Text] [Related]
4. A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus.
Staels B
Postgrad Med; 2009 May; 121(3 Suppl 1):25-30. PubMed ID: 19494475
[TBL] [Abstract][Full Text] [Related]
5. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice.
Potthoff MJ; Potts A; He T; Duarte JA; Taussig R; Mangelsdorf DJ; Kliewer SA; Burgess SC
Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(4):G371-80. PubMed ID: 23257920
[TBL] [Abstract][Full Text] [Related]
6. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.
Beysen C; Murphy EJ; Deines K; Chan M; Tsang E; Glass A; Turner SM; Protasio J; Riiff T; Hellerstein MK
Diabetologia; 2012 Feb; 55(2):432-42. PubMed ID: 22134839
[TBL] [Abstract][Full Text] [Related]
7. Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes.
Hansen M; Sonne DP; Knop FK
Curr Diab Rep; 2014; 14(5):482. PubMed ID: 24623198
[TBL] [Abstract][Full Text] [Related]
8. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism.
Brufau G; Stellaard F; Prado K; Bloks VW; Jonkers E; Boverhof R; Kuipers F; Murphy EJ
Hepatology; 2010 Oct; 52(4):1455-64. PubMed ID: 20725912
[TBL] [Abstract][Full Text] [Related]
9. Bile acid sequestrants: glucose-lowering mechanisms.
Prawitt J; Staels B
Metab Syndr Relat Disord; 2010 Dec; 8 Suppl 1():S3-8. PubMed ID: 20977365
[TBL] [Abstract][Full Text] [Related]
10. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
[TBL] [Abstract][Full Text] [Related]
11. Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors.
Spinelli V; Chávez-Talavera O; Tailleux A; Staels B
Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):138-44. PubMed ID: 26859552
[TBL] [Abstract][Full Text] [Related]
12. Bile acid treatment and FXR agonism lower postprandial lipemia in mice.
Farr S; Stankovic B; Hoffman S; Masoudpoor H; Baker C; Taher J; Dean AE; Anakk S; Adeli K
Am J Physiol Gastrointest Liver Physiol; 2020 Apr; 318(4):G682-G693. PubMed ID: 32003602
[TBL] [Abstract][Full Text] [Related]
13. The use of the bile acid sequestrant colesevelam HCl in patients with type 2 diabetes mellitus: for glucose and lipid control. Introduction.
Handelsman Y
Postgrad Med; 2009 May; 121(3 Suppl 1):5-6. PubMed ID: 19494471
[No Abstract] [Full Text] [Related]
14. MECHANISMS IN ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases.
Sonne DP
Eur J Endocrinol; 2021 May; 184(5):R193-R205. PubMed ID: 33630750
[TBL] [Abstract][Full Text] [Related]
15. The Role of Bile Acids in Glucose Metabolism and Their Relation with Diabetes.
González-Regueiro JA; Moreno-Castañeda L; Uribe M; Chávez-Tapia NC
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):16-21. PubMed ID: 29118282
[TBL] [Abstract][Full Text] [Related]
16. Bile acids as regulators of hepatic lipid and glucose metabolism.
Trauner M; Claudel T; Fickert P; Moustafa T; Wagner M
Dig Dis; 2010; 28(1):220-4. PubMed ID: 20460915
[TBL] [Abstract][Full Text] [Related]
17. Role of Bile Acids in the Regulation of Food Intake, and Their Dysregulation in Metabolic Disease.
Xie C; Huang W; Young RL; Jones KL; Horowitz M; Rayner CK; Wu T
Nutrients; 2021 Mar; 13(4):. PubMed ID: 33800566
[TBL] [Abstract][Full Text] [Related]
18. Intestinal bile acid receptors are key regulators of glucose homeostasis.
Trabelsi MS; Lestavel S; Staels B; Collet X
Proc Nutr Soc; 2017 Aug; 76(3):192-202. PubMed ID: 27846919
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells.
Trabelsi MS; Daoudi M; Prawitt J; Ducastel S; Touche V; Sayin SI; Perino A; Brighton CA; Sebti Y; Kluza J; Briand O; Dehondt H; Vallez E; Dorchies E; Baud G; Spinelli V; Hennuyer N; Caron S; Bantubungi K; Caiazzo R; Reimann F; Marchetti P; Lefebvre P; Bäckhed F; Gribble FM; Schoonjans K; Pattou F; Tailleux A; Staels B; Lestavel S
Nat Commun; 2015 Jul; 6():7629. PubMed ID: 26134028
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus.
Bays HE; Cohen DE
Curr Med Res Opin; 2007 Jul; 23(7):1673-84. PubMed ID: 17588297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
